摘要
目的 探讨P15、P16与胃癌发生及临床病理因素的关系。方法 应用免疫组织化学方法测定 80例存档胃癌标本中P15、P16表达。结果 P15阳性率在胃癌组为 43 .15 % ,胃良性病变组为 6 9.2 3 % (P <0 .0 5 ) ,P15表达与临床病理因素无关。P16于胃癌中阳性表达率为 2 0 .0 0 % ,胃良性病变组为 5 5 .0 0 % (P <0 .0 1) ,P16阳性率与大体类型、分化程度、远处转移及pTNM分期无关。P16阳性率于浸润深度不超过粘膜下层组为 71.43 % ,浸润肌层组为 17.2 4% ,浸润浆膜层组为 13 .6 4% (P <0 .0 1) ;有淋巴结转移组为 12 .96 % ,无淋巴结转移组为 34.6 2 % (P <0 .0 5 )。P15、P16表达密切相关 (P <0 .0 1)。结论 胃癌中存在P15、P16表达下调 ;P15与临床病理因素无关 ,P16与浸润深度、淋巴结转移有关 ;
Objective To investigate the relationship between P15、P16 and gastric cancer(GS).Methods Immunohistochemical staining was used to examine the expressions of P15 and P16 in archival wax embeded spcimens of GC.Results The positive expression rate(PER)of P15 was 43.15% in GC,69.23% in gastric benign disease(GBD)(P<0.05),but no relatioship was found between PER of P15 and clinicopathologic factors.The PER of P16 was 20% in GC,55% in GBD(P<0.01).The PER of P16 had,no significant correlation with optical types,histological types,distant metastasis and PTNM stages.The PER of P16 was 71.43% in invasive mucosa or submucosa group,17.24% in invasive inherent muscle group and 13.64% in invasive serosa group(P<0.01);12.96% in GC with lymph node metastasis,34.62% in GC without lymph node metastasis(P<0.05). Conclusions P15 and P16 show down regulation in GC;P15 has no relationship with clinicopathologic factors;P16 has relationship with invasive depth and lymph node metastasis;there is correlation between the expression of P15 and P16.
出处
《中国肿瘤临床与康复》
2001年第2期23-24,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
